February 2023

Perfuze Round

Perfuze Announces FDA Clearance and First U.S. Clinical Use of Millipede 088 Access Catheter.

Latest News, Perfuze /

Galway, Ireland. 16 February 2023.  Perfuze, a medical device company developing next-generation catheter-based technology to treat acute ischemic stroke, has secured its first product clearance from the U.S. Food and Drug Administration (FDA) for the company’s Millipede 088 Access Catheter.  The first U.S. clinical procedures with Millipede 088 were successfully performed by physicians at Stony […]

Perfuze Announces FDA Clearance and First U.S. Clinical Use of Millipede 088 Access Catheter. Read More »

Fusion Round

Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer.

Fusion, Latest News /

Hamilton, ON, Canada and Boston, MA, USA. 13 February 2023.  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) (“Fusion”), a clinical-stage oncology company focused on developing next-generation targeted alpha therapies (“TATs”) as precision medicines, today announced the acquisition from RadioMedix, Inc. (“RadioMedix”) of the investigational new drug application (“IND”) for an ongoing Phase 2 clinical trial (the “TATCIST”

Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer. Read More »

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top